It was a pleasure to meet with Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss the CENTAUR study findings, and where AMX0035 is likely to be placed in the treatment paradigm for amyotrophic lateral sclerosis (ALS).
The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- Could you tell us a little about the CENTAUR study and its findings? (0:06)
- What has the recent analysis taught us about the long term efficacy and safety of AMX0035? (1:31)
- Where is AMX0035 likely to be placed in the treatment paradigm for ALS? (2:18)
Disclosures: Sabrina Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma, Biohaven, Clene, Prilenia, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association; and reports personal consulting fees for advisory panels from Orion.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
